Phospho-RIP3 (Ser232) Antibody - #AF7443

Fig. 1 RIPK1/RIPK3 silencing inhibited HGF-induced necroptosis. Representative images and percentages of RIPK1/ser166-p-RIPK1 (A–C) and RIPK3/ser232-p-RIPK3 (D–F). Percentages of apoptotic and necrotic cells (G–L). n = 3 per group. Means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. NGF normal glucose and fat group, HGF high glucose and high fat group.

FIGURE 2 CHBP inhibits necroptosis in random-pattern skin flaps. (a,b) Representative immunohistochemical staining for RIPK3 (brown) in mouse skin tissues from the control, FLAP and FLAP + CHBP groups and quantification of integrated absorbance of RIPK3 signal (n = 6 mice per group). The tissues were counterstained with haematoxylin (blue; scale bar = 100 μm). (c,d) Representative images of immunofluorescence staining of mouse skin samples (DAPI staining of the nuclei) and quantification graph for RIPK1 (green)-positive cells (n = 6 mice per group). Scale bar: 10 μm. Skin samples were harvested from mice in the control, FLAP and FLAP + CHBP groups. (e–g) CHBP treatment attenuated the activation of RIPK1, RIPK3 and MLKL induced by ischaemia–reperfusion injury. The expression of caspase 8 (CASP8) was significantly increased, which has an inhibitory effect on necroptosis. Densitometric quantification is shown (n = 6 mice per group). Data shown are means ± SEM. *P